Navigation Links
PuraMed BioScience Partners with Operation Troop Aid to Sponsor Care Packages
Date:7/22/2014

SCHOFIELD, Wis., July 22, 2014 /PRNewswire/ -- PuraMed BioScience®, Inc., (OTCBB: PMBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced today that the company is a corporate sponsor of Operation Troop Aid.

"We are pleased to sponsor Operation Troop Aid," said Russell Mitchell, CEO and Chairman of PuraMed BioScience. "Research shows that many service men and women in combat zones experience migraines much more frequently than the general population. Providing those people with LipiGesic® M, our highly effective migraine medication, can help them relieve migraines while they are serving our country."

Currently, Operation Troop Aid ships between 15 and 20 thousand individual care packages overseas to deployed service men and women each year. Operation Troop Aid's future expansion plans include a veteran's care network that will incorporate music therapy and recovery retreats in addition to the development of a special care-package program for children whose mothers or fathers are deployed.

"We appreciate PuraMed's generous donation of LipiGesic M to our program," said Mark H. Woods, LT (03-E) USN Ret, CEO of Troop Aid. "Our Troops have been on exhaustive arduous deployments during the last 13 years. Some have been deployed as many as 10 times. Operation Troop Aid care packages provide our troops with encouragement from home and proof that people in their homeland care about them and appreciate what they are doing."

"Operation Troop Aid's mission to provide assistance and encouragement to military personnel and veterans aligns with our passion to help people who suffer from debilitating migraines," said Mitchell. "We know that many service men and women who have experienced combat have a higher incidence of migraine, which is often accompanied by Post Traumatic Stress Disorder (PTSD). Introducing military personnel to LipiGesic M during deployment can also help them as they return to civilian life, especially if they experience PTSD, since LipiGesic M does not interfere with commonly prescribed PTSD medications. We look forward to working with Operation Troop Aid."

About LipiGesic® M

LipiGesic M is a clinically tested, all-natural, over-the-counter migraine headache pain relief medication that quickly stops disabling migraine pain and associated symptoms. LipiGesic M's feverfew and ginger gel is non-drowsy and non-habit forming. Unlike the commonly prescribed prescription and OTC migraine treatments, LipiGesic M is not associated with rebound headaches. LipiGesic M has an excellent safety profile and has no reported drug interactions.  

About Operation Troop Aid

In 2003, Operation Troop Aid incorporated as a charity and was granted non-profit 501c3 status by the Internal Revenue Service. Operation Troop Aid is a Premier Care Package and Bill Assistance Charity for all branches of the U.S. military. The mission of Operation Troop Aid is to make a positive difference and inspire U.S. service members by:

  • distributing Care Packages to U.S. Troops who are deployed
  • providing human and social services to help military personnel and veterans who have needs not met by other agencies
  • facilitating community awareness programs to initiate communication between communities and the Troops

Operation Troop Aid raises funds through major concert promotions, entertainment initiatives, and the generosity of corporate and individual sponsors, and local community fund drives and events. For more information about Operation Troop Aid visit www.operationtroopaid.org.

About PuraMed BioScience, Inc.

PuraMed BioScience engages in the research, development, and marketing of non-prescription medicinal and healthcare products. In addition to LipiGesic M, PuraMed BioScience plans to launch additional cannabinoid-enhanced, anti-inflammatory, and anxiolytic products as it moves forward in the development of its CBD product line.

Forward-Looking Statements

This news release contains forward-looking statements regarding PuraMed BioScience, Inc., and its future business plans, which statements involve known and unknown risks and uncertainties. Such risks and uncertainties may cause actual results and future achievements of PuraMed BioScience to be materially different from those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.

Contact:
PuraMed BioScience, Inc.
Russell Mitchell, Chairman and CEO
715-359-6373
rmitchell@PuramedBioScience.com
www.PuramedBioScience.com


'/>"/>
SOURCE PuraMed BioScience, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. PuraMed BioScience Invited to Discuss LipiGesic M on Armed Forces Network
2. PuraMed BioScience Sponsors Miles for Migraine Race with LipiGesic M
3. PuraMed BioScience Discusses Potential for Patent Portfolio Acquisition
4. Pressure BioSciences to Develop Front-end Sample Preparation for Parabase Genomics Targeted Next Generation Sequencing Testing Platform
5. Attention Regado Biosciences, Inc. Investors: Regado Misled Investors According to a Recently Filed Class Action
6. Meditope Biosciences Appoints Prominent Scientific Advisory Board
7. Sangamo BioSciences to Focus on Advancing ZFP Therapeutic Pipeline at J.P. Morgan Healthcare Conference
8. Coherus Biosciences Invited to Present at 2014 J.P. Morgan Annual Healthcare Conference
9. Coherus Biosciences als Präsentator zur J.P. Morgan Annual Healthcare Conference 2014 eingeladen
10. Regado Biosciences, Inc. Adds World-Class Interventional Cardiologist and Researcher to Medical Advisory Board
11. Calithera Biosciences Presents Data for CB-839 in Triple-Negative Breast Cancer Models at the 2013 San Antonio Breast Cancer Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 Any dentist who has ... of the current process. Many of them do not even ... technical difficulties and high laboratory costs involved. And those who ... it at such a high cost that the majority of ... Dr. Parsa Zadeh , founder of Dental Evolutions ...
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
(Date:6/23/2016)... Ill. and BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment ... Astellas Farma Brasil as the company,s second affiliate in Latin America . ... ... General Manager of Astellas Farma Colombia ... ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... Dallas, Texas (PRWEB) , ... June 24, 2016 ... ... 12th International Conference and Scientific Sessions in Dallas that it will receive two ... Announcement of the grants came as PHA marked its 25th anniversary by recognizing ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their pencils ... an essay contest in which patients and their families pay tribute to a genetic ... 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm Slone Partners ... extensive sequencing and genomics experience, as Vice President of North American Capital Sales at ... responsible for leading the sales team in the commercialization of the HTG EdgeSeq system ...
Breaking Medicine News(10 mins):